leadf
logo-loader
viewAlbert Labs

Albert Labs announces chairs for its clinical and scientific advisory boards

The psychedelic medicine company named Professor Jo Neill as chair of the Clinical Advisory Board and Parminder Singh to head the Scientific Advisory Board

Albert Labs - Albert Labs announces chairs for its clinical and scientific advisory boards
Albert Labs leverages Real-World Evidence studies across Europe to accelerate access to its proprietary psilocybin-based therapy for patients with urgent, unmet mental health needs

Albert Labs has announced the chairs for its clinical and scientific advisory boards. 

In a statement, the private psychedelic medicine company said it has appointed Professor Jo Neill as chair of the Clinical Advisory Board and Parminder Singh to head the Scientific Advisory Board.

“We are delighted to have such authority with Jo and Parminder, they bring a wealth of knowledge and expertise in each of their disciplines and we look forward to working with them in driving our Clinical and Scientific Advisory boards,” said Graeme McFarlane, the company’s chief commercial officer.

READ: Albert Labs announces C$4M financing ahead of CSE listing

Albert Labs leverages Real-World Evidence (RWE) studies across Europe to accelerate access to its proprietary psilocybin-based therapy for patients with urgent, unmet mental health needs.

The company noted that Neill is a professor of psychopharmacology at the University of Manchester (Division of Pharmacy & Optometry). She is also chair of the Medical Psychedelics Working Group for Drug Science, a scientific advisor for Heroic Hearts UK.

Singh, it said, is a seasoned executive with more than 30 years of technical, operations, international business, and management experience in both corporate and entrepreneurial environments. His previous experience includes his role as CEO of LifeLens Technologies, an innovation company.

For their new roles, Albert Labs said Neill will help guide decisions on the running of the RWE trials program, while Singh and the Scientific Advisory Board will work directly with the company’s laboratory team and be responsible for IP protection and development of novel manufacturing technologies through natural cultivation, extraction, formulation, and delivery.

The company said it expects to announce completely staffed boards with additional expertise in psychology, psychiatry, palliative care, and oncology as well as mycology and medicinal plant licencing and compliance.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Albert Labs announces distinguished clinical and scientific advisory boards

Albert Labs Chief Commercial Officer Graeme Mcfarlane joins Proactive London to introduce additions to the Clinical Advisory Board, chaired by Professor Jo Neill. Neill will bring her expertise in psychology, psychiatry, palliative care and oncology. This multidisciplinary team will help...

on 25/6/21

2 min read